Ganciclovir (Synonyms: BW 759; 2'-Nor-2'-deoxyguanosine)

Name: Ganciclovir
Brand: MedChemExpress
SKU: HY-13637
Rating: 5.0 (18 reviews)

Cat. No.: HY-13637 Purity: 99.89%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Ganciclovir (BW 759), a nucleoside analogue, is an orally active antiviral agent with activity against CMV. Ganciclovir also has activity in vitro against members of the herpes group and some other DNA viruses. Ganciclovir inhibits the in vitro replication of human herpes viruses (HSV 1 and 2, CMV) and adenovirus serotypes 1, 2, 4, 6, 8, 10, 19, 22 and 28. Ganciclovir has an IC₅₀ of 5.2 μM for feline herpesvirus type-1 (FHV-1) and can diffuse into the brain.

For research use only. We do not sell to patients.

Ganciclovir Chemical Structure

CAS No. : 82410-32-0

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 70	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 70	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	USD 64	In-stock	Estimated Time of Arrival: December 31
1 g	USD 97	In-stock	Estimated Time of Arrival: December 31
5 g	USD 128	In-stock	Estimated Time of Arrival: December 31
10 g		Get quote
50 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 18 publication(s) in Google Scholar

Other Forms of Ganciclovir:

17 Publications Citing Use of MCE Ganciclovir

: Ganciclovir purchased from MedChemExpress. Usage Cited in: Eur J Pharm Sci. 2019 Jan 15;127:29-37. [Abstract]; Viral reporter GFP expression after inoculation and compound treatment. Infected cells treated with DMSO control, BIO, Ganciclovir (GCV) or Letermovir (LTR)

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HSV Isoform Specific Products:

View All Isoforms

HSV-1 HSV-2 HSV

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[2]^[3]

CMV

HSV-1

HSV-2

FHV-1

5.2 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
BC-3	IC₅₀	70 μM Compound: GCV	Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay Cytotoxicity against Kaposi's sarcoma-associated herpesvirus infected BC3 cells after 120 hrs by MTT assay	[PMID: 17402726]
BJ	EC₅₀	3 μM Compound: GCV	Antiviral activity against Human cytomegalovirus Towne infected in human hhTERT-BJ1 cells assessed as inhibition of virus mediated DNA synthesis after 2 days Antiviral activity against Human cytomegalovirus Towne infected in human hhTERT-BJ1 cells assessed as inhibition of virus mediated DNA synthesis after 2 days	[PMID: 18458124]
Bone marrow cell	CC₅₀	30 μM Compound: ganciclovir	Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days Cytotoxicity against human bone marrow cells assessed as inhibition of CFU-GM formation after 15 days	[PMID: 17329103]
BSC-1	IC₅₀	3.5 μM Compound: GCV (table-1)	Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay	[PMID: 15509176]
BSC-1	IC₅₀	3.5 μM Compound: GCV (ganciclovir) (table-1)	Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay	[PMID: 15509175]
BSC-1	IC₅₀	3.5 μM Compound: GCV (ganciclovir) (table-1)	Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay Inhibitory concentration required against herpes simplex virus type-1 (HSV-1) expressed in BSC-1 cells was determined by ELISA assay	[PMID: 15509174]
BSC-1	IC₅₀	3.5 μM Compound: Ganciclovir	ELISA assay was performed using BSC-1 cells to determine activity against HSV-1 ELISA assay was performed using BSC-1 cells to determine activity against HSV-1	[PMID: 10882372]
BSC-1	IC₅₀	3.5 μM Compound: Ganciclovir	Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells Antiviral activity against HSV-1 (herpes simplex virus), determined by ELISA in quadruplicate wells using BSC-1 cells	[PMID: 10882370]
CCRF-CEM	CC₅₀	> 100 μM Compound: 1	Cytostatic activity human CEM cells assessed as reduction in cell viability after 72 hrs by cell counting method Cytostatic activity human CEM cells assessed as reduction in cell viability after 72 hrs by cell counting method	[PMID: 28829913]
CCRF-CEM	IC₅₀	> 390 μM Compound: Ganciclovir	In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity In vitro anti-HIV screen using HIV-1 infected CD4 lymphocytes (CEM cell line), determines cytotoxicity	[PMID: 11814776]
DG-75	IC₅₀	> 100 μM Compound: GCV	Cytotoxicity against DG75 cells after 120 hrs by MTT assay Cytotoxicity against DG75 cells after 120 hrs by MTT assay	[PMID: 17402726]
E6SM	EC₅₀	> 100 μg/mL Compound: ganciclovir	Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce vaccinia virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
E6SM	EC₅₀	> 100 μM Compound: Gancyclovir, DHPG	Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines	[PMID: 11495586]
E6SM	EC₅₀	0.0012 μM Compound: Gancyclovir, DHPG	Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines	[PMID: 11495586]
E6SM	EC₅₀	0.0012 μM Compound: Gancyclovir, DHPG	Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines	[PMID: 11495586]
E6SM	EC₅₀	0.003 μg/mL Compound: ganciclovir	Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce HSV-2 strain G virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
E6SM	EC₅₀	0.004 μg/mL Compound: ganciclovir	Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce HSV-1 strain KOS virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
E6SM	EC₅₀	2.4 μg/mL Compound: ganciclovir	Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture Effective concentration required to reduce HSV-1 strain KOS ACV virus plaque formation by 50% in E6SM Cell Culture	[PMID: 15481985]
Fibroblast	EC₅₀	1.2 μM Compound: 10	Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay	[PMID: 19397271]
Fibroblast	IC₅₀	3.4 μM Compound: 1 (BW-B759U, ganciclovir)	Inhibition of growth of human cytomegalovirus (HCMV) was determined by plaque reduction assay in human lung fibroblast cell line Inhibition of growth of human cytomegalovirus (HCMV) was determined by plaque reduction assay in human lung fibroblast cell line	[PMID: 2826784]
Fibroblast	EC₅₀	5.5 μM Compound: 10	Antiviral activity against Murine cytomegalovirus infected in mouse embryonic fibroblast cells by plaque reduction assay Antiviral activity against Murine cytomegalovirus infected in mouse embryonic fibroblast cells by plaque reduction assay	[PMID: 19397271]
HEL	EC₅₀	> 100 μg/mL Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	> 100 μg/mL Compound: Ganciclovir	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	> 100 μg/mL Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	> 100 μg/mL Compound: Ganciclovir	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	> 100 μg/mL Compound: ganciclovir	Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	> 100 μg/mL Compound: ganciclovir	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	> 100 μg/mL Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	> 100 μg/mL Compound: Ganciclovir	Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	> 100 μM Compound: Ganciclovir	Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	> 100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	> 100 μM Compound: Ganciclovir	Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	> 100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	> 100 μM Compound: Ganciclovir	Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Vesicular stomatitis virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	> 100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Vaccinia virus infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	EC₅₀	> 100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	> 100 μM Compound: Ganciclovir	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	> 100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	> 100 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	CC₅₀	> 100 μM Compound: Ganciclovir	Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	> 100 μM Compound: Ganciclovir	Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	> 100 μM Compound: Ganciclovir	Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	> 100 μM Compound: Ganciclovir	Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	> 100 μM Compound: Ganciclovir	Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method	[PMID: 20034711]
HEL	CC₅₀	> 150 μM Compound: ganciclovir	Cytotoxic concentration required to reduce HEL cell growth by 50% Cytotoxic concentration required to reduce HEL cell growth by 50%	[PMID: 15481985]
HEL	CC₅₀	> 150 μM Compound: DHPG(ganciclovir)	Cytotoxic concentration required to reduce HEL cell growth by 50% Cytotoxic concentration required to reduce HEL cell growth by 50%	[PMID: 15081019]
HEL	CC₅₀	> 200 μg/mL Compound: GCV	Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells. Tested for the cytotoxic concentration, required to reduce cell growth by 50% in human embryonic lung (HEL) cells.	[PMID: 7877148]
HEL	CC₅₀	> 200 μM Compound: GCV	Cytotoxicity against HEL cells after 3 days Cytotoxicity against HEL cells after 3 days	[PMID: 17622128]
HEL	CC₅₀	> 250 μM Compound: Ganciclovir	Cytotoxicity against HEL cells after 3 days by coulter counter analysis Cytotoxicity against HEL cells after 3 days by coulter counter analysis	[PMID: 21232828]
HEL	CC₅₀	> 300 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method Cytotoxicity against human HEL cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method	[PMID: 33894564]
HEL	CC₅₀	> 319 μM Compound: Ganciclovir	Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method Cytotoxicity against HEL cells assessed as reduction in cell viability after 3 days by coulter counting method	[PMID: 29670705]
HEL	CC₅₀	> 350 μM Compound: Ganciclovir	Cytostatic activity against HEL cells after 3 days by Coulter counting method Cytostatic activity against HEL cells after 3 days by Coulter counting method	[PMID: 29407990]
HEL	CC₅₀	> 350 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells after 3 days by Coulter counting method Cytotoxicity against human HEL cells after 3 days by Coulter counting method	[PMID: 23911854]
HEL	CC₅₀	> 391 μM Compound: Ganciclovir	Cytostatic activity against HEL cells after 3 days by Coulter counting method Cytostatic activity against HEL cells after 3 days by Coulter counting method	[PMID: 29550734]
HEL	CC₅₀	> 391 μM Compound: Ganciclovir	Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method Cytotoxic activity against HEL cells assessed as reduction in cell proliferation after 3 days by coulter counting method	[PMID: 28682067]
HEL	CC₅₀	> 394 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method Cytotoxicity against human HEL cells assessed as reduction in cell proliferation incubated for 3 days by Coulter counter method	[PMID: 32676147]
HEL	CC₅₀	> 50 μg/mL Compound: Ganciclovir	Cytotoxic concentration reducing HEL cell growth by 50%. Cytotoxic concentration reducing HEL cell growth by 50%.	[PMID: 12217359]
HEL	CC₅₀	> 50 μg/mL Compound: Ganciclovir	The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells The concentration required to reduce cell growth by 50% was measured on Human Embryonic Lung (HEL) cells	[PMID: 10197958]
HEL	IC₅₀	> 50 μM Compound: DHPG	The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50% The compound was tested for cytotoxic concentration required to reduce human embryonic lung cell growth by 50%	[PMID: 10411487]
HEL	EC₅₀	≥ 20 μM Compound: Ganciclovir	Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against acyclovir-resistant thymidine kinase negative Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	CC₅₀	≥ 319 μM Compound: GCV	Cytotoxicity against human cytomegalovirus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method Cytotoxicity against human cytomegalovirus infected HEL cells assessed as cell growth inhibition incubated for 3 days by coulter counter method	[PMID: 26443550]
HEL	EC₅₀	≥ 93 μM Compound: Ganciclovir	Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay Antiviral activity against Vaccinia virus Lederie infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	IC₅₀	0.02 μg/mL Compound: GCV	Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%. Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain OKA plaque formation by 50%.	[PMID: 7877148]
HEL	EC₅₀	0.02 μM Compound: Ganciclovir	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	0.027 μM Compound: Ganciclovir	Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay Antiviral activity against HSV1 KOS infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	0.029 μM Compound: Ganciclovir	Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay Antiviral activity against HSV2 G infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	EC₅₀	0.03 μg/mL Compound: Ganciclovir	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	0.03 μg/mL Compound: Ganciclovir	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	[PMID: 20034711]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	0.03 μM Compound: Ganciclovir	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	EC₅₀	0.05 μg/mL Compound: Ganciclovir	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	0.05 μM Compound: Ganciclovir	Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	0.06 μg/mL Compound: Ganciclovir	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	0.06 μg/mL Compound: Ganciclovir	Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	EC₅₀	0.07 μg/mL Compound: Ganciclovir	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	0.07 μM Compound: Ganciclovir	Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Human herpesvirus 2 strain G infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	IC₅₀	0.072 μg/mL Compound: GCV	Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50% Tested for the inhibitory concentration required to reduce TK+ Varicella-Zoster virus (TK+ VZV) strain YS plaque formation by 50%	[PMID: 7877148]
HEL	EC₅₀	0.08 μg/mL Compound: ganciclovir	Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	0.08 μg/mL Compound: ganciclovir	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	0.08 μM Compound: Ganciclovir	Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	0.08 μM Compound: Ganciclovir	Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	0.08 μM Compound: Ganciclovir	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	0.09 μM Compound: Ganciclovir	Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay Antiviral activity against Human herpesvirus 1 strain KOS infected human HEL cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	[PMID: 32214762]
HEL	IC₅₀	0.1 μg/mL Compound: GCV	Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%. Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain 07/1 plaque formation by 50%.	[PMID: 7877148]
HEL	EC₅₀	0.5 μM Compound: ganciclovir	Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce CMV AD169 strain virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	EC₅₀	0.51 μg/mL Compound: ganciclovir	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17869124]
HEL	EC₅₀	0.59 μM Compound: 1b, GCV	Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days Antiviral activity against Varicella zoster virus OKA infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days	[PMID: 19339082]
HEL	EC₅₀	0.8 μg/mL Compound: ganciclovir	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17869124]
HEL	EC₅₀	0.8 μM Compound: Ganciclovir	Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis Antiviral activity against acyclovir-resistant TK-deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathic effect after 4 days by microscopic analysis	[PMID: 21696963]
HEL	IC₅₀	0.9 μg/mL Compound: GCV	Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%. Tested for the inhibitory concentration required to reduce thymidine kinase deficient Varicella-Zoster virus (TK- VZV) strain YS/R plaque formation by 50%.	[PMID: 7877148]
HEL	EC₅₀	1 μg/mL Compound: Ganciclovir	Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	[PMID: 18851889]
HEL	IC₅₀	1 μM Compound: DHPG	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus AD-169 strain The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus AD-169 strain	[PMID: 10411487]
HEL	EC₅₀	1.1 μM Compound: 1b, GCV	Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days Antiviral activity against Varicella zoster virus YS infected in human HEL cells assessed as inhibition of virus induced cytopathicity after 5 days	[PMID: 19339082]
HEL	EC₅₀	1.3 μM Compound: ganciclovir	Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days Antiviral activity against HCMV Davis infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days	[PMID: 17961851]
HEL	EC₅₀	1.3 μM Compound: ganciclovir	Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days Antiviral activity against human cytomegalovirus Davis in HEL cells assessed as reduction of plaque formation after 7days	[PMID: 17539622]
HEL	EC₅₀	1.5 μM Compound: Ganciclovir	Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection Effective concentration required to inhibit human cytomegalo virus Davis induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection	[PMID: 15801851]
HEL	EC₅₀	1.5 μM Compound: Ganciclovir	Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection Effective concentration required to inhibit human cytomegalo virus AD-169 induced cytopathicity in HEL fibroblast cell line after 7 days of postinfection	[PMID: 15801851]
HEL	EC₅₀	1.5 μM Compound: ganciclovir	Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture Effective concentration required to reduce CMV davis strain virus plaque formation by 50% in HEL cell culture	[PMID: 15481985]
HEL	EC₅₀	1.65 μM Compound: Ganciclovir	Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days Antiviral activity against Cytomegalovirus AD-169 infected in HEL cells assessed as inhibition of virus plaque formation after 4 days	[PMID: 22459876]
HEL	EC₅₀	1.65 μM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days Antiviral activity against Human cytomegalovirus Davis infected in HEL cells assessed as inhibition of virus plaque formation after 4 days	[PMID: 22459876]
HEL	EC₅₀	100 μM Compound: Ganciclovir	Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	[PMID: 22459876]
HEL	EC₅₀	11.8 μM Compound: Gancyclovir, DHPG	Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in Davis-169 strain HEL cell lines Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in Davis-169 strain HEL cell lines	[PMID: 11495586]
HEL	EC₅₀	12.6 μM Compound: 1b, GCV	Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection Antiviral activity against human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection	[PMID: 19339082]
HEL	CC₅₀	122 μg/mL Compound: gancyclovir	Cytotoxicity against HEL cells assessed as cell growth after 3 days Cytotoxicity against HEL cells assessed as cell growth after 3 days	[PMID: 17948980]
HEL	EC₅₀	13 μM Compound: Ganciclovir	Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days Antiviral activity against Cytomegalovirus AD169 infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days	[PMID: 32676147]
HEL	CC₅₀	130 μM Compound: Ganciclovir	Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter Cytostatic against human HEL cells assessed as reduction in cell growth after 3 days by coulter counter	[PMID: 22578783]
HEL	CC₅₀	134 μM Compound: GCV, ganciclovir	Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days Cytotoxicity against human HEL cells assessed as reduction of growth after 3 days	[PMID: 19226140]
HEL	EC₅₀	14.7 μM Compound: Ganciclovir	Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay Antiviral activity against thymidine kinase negative and ACV resistant HSV1 KOS infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	CC₅₀	146 μg/mL Compound: ganciclovir	Cytotoxicity against HEL cells assessed as reduction of growth after 3 days Cytotoxicity against HEL cells assessed as reduction of growth after 3 days	[PMID: 18835175]
HEL	CC₅₀	146 μg/mL Compound: ganciclovir	Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days Cytotoxicity against HEL cells assessed as reduction of cell growth after 3 days	[PMID: 17869124]
HEL	CC₅₀	164 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells after 3 days Cytotoxicity against human HEL cells after 3 days	[PMID: 21128666]
HEL	CC₅₀	172 μM Compound: ganciclovir	Cytotoxicity against HEL cells assessed as cell growth after 7 days Cytotoxicity against HEL cells assessed as cell growth after 7 days	[PMID: 17539622]
HEL	EC₅₀	2 μg/mL Compound: Ganciclovir	Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	[PMID: 20724039]
HEL	EC₅₀	2 μM Compound: GCV, ganciclovir	Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection Antiviral activity against HCMV AD169 infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection	[PMID: 19226140]
HEL	EC₅₀	2.3 μM Compound: GCV	Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days Antiviral activity against TK+ VZV YS in HEL cells assessed as reduction of virus plaque formation after 5 days	[PMID: 17622128]
HEL	EC₅₀	2.5 μM Compound: 1b, GCV	Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days Antiviral activity against thymidine kinase deficient Varicella zoster virus 07/1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 5 days	[PMID: 19339082]
HEL	EC₅₀	2.5 μM Compound: 1b, GCV	Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection Antiviral activity against human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 7 days post infection	[PMID: 19339082]
HEL	EC₅₀	2.6 μM Compound: ganciclovir	Antiviral activity against CMV Davis in human HEL cells after 7 days Antiviral activity against CMV Davis in human HEL cells after 7 days	[PMID: 17672445]
HEL	IC₅₀	2.7 μg/mL Compound: Ganciclovir	Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Davis using HEL cell line Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Davis using HEL cell line	[PMID: 15745823]
HEL	IC₅₀	2.9 μg/mL Compound: GCV	Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%. Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain AD-169 plaque formation by 50%.	[PMID: 7877148]
HEL	CC₅₀	221 μM Compound: 1b, GCV	Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days Cytotoxicity against human HEL cells assessed as reduction in cell growth after 3 days	[PMID: 19339082]
HEL	CC₅₀	231 μM Compound: Ganciclovir	Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay Cytotoxicity against HEL cells assessed as effect on cell growth incubated for 3 days by Coulter counter assay	[PMID: 22858222]
HEL	CC₅₀	231.22 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis	[PMID: 33479570]
HEL	CC₅₀	273 μM Compound: 1	Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method Cytotoxicity against human HEL cells assessed as cell growth inhibition by cell counting method	[PMID: 28829913]
HEL	EC₅₀	3 μM Compound: Ganciclovir	Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against acyclovir-resistant thymidine kinase deficient HSV1 KOS infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	3.6 μM Compound: GCV, ganciclovir	Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection Antiviral activity against HCMV Davis infected in human HEL cells assessed inhibition of virus-induced cytopathicity after 7 days postinfection	[PMID: 19226140]
HEL	CC₅₀	308 μM Compound: Ganciclovir	Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method Cytotoxicity against HEL cells assessed as reduction in cell growth after 3 days by coulter counter method	[PMID: 28757102]
HEL	CC₅₀	328.5 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells assessed as cell growth reduction incubated for 3 days Cytotoxicity against human HEL cells assessed as cell growth reduction incubated for 3 days	[PMID: 26291038]
HEL	EC₅₀	4.44 μM Compound: Ganciclovir	Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days Antiviral activity against Cytomegalovirus Davis infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity measured after 6 to 7 days	[PMID: 32676147]
HEL	EC₅₀	4.72 μM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy Antiviral activity against Human cytomegalovirus Davis expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy	[PMID: 26291038]
HEL	EC₅₀	4.8 μM Compound: ganciclovir	Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days Antiviral activity against HCMV AD169 infected in HEL cells assessed as reduction of virus-induced cytopathogenicity after 3 days	[PMID: 17961851]
HEL	EC₅₀	4.8 μM Compound: ganciclovir	Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days Antiviral activity against human cytomegalovirus AD169 in HEL cells assessed as reduction of plaque formation after 7 days	[PMID: 17539622]
HEL	CC₅₀	435 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter Cytotoxicity against human HEL cells assessed as growth inhibition after 3 days by coulter counter	[PMID: 21565516]
HEL	IC₅₀	5 μM Compound: DHPG	The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus Davis strain The compound was tested for antiviral activity by measuring the concentration required to reduce plaque formation against cytomegalo virus Davis strain	[PMID: 10411487]
HEL	EC₅₀	5.1 μM Compound: GCV	Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against HCMV AD169 in HEL cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17622128]
HEL	EC₅₀	5.2 μM Compound: Ganciclovir	Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days Antiviral activity against HCMV AD169/Davis infected in human HEL cells assessed as reduction of virus-induced cytopathogenicity after 7 days	[PMID: 21128666]
HEL	EC₅₀	5.9 μM Compound: Ganciclovir	Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay Antiviral activity against HCMV Davis infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL	CC₅₀	543 μM Compound: Ganciclovir	Cytotoxicity against human HEL cells after 3 days by coulter counter Cytotoxicity against human HEL cells after 3 days by coulter counter	[PMID: 21745746]
HEL	EC₅₀	58 μg/mL Compound: Ganciclovir	Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	[PMID: 20971531]
HEL	EC₅₀	6 μg/mL Compound: ganciclovir	Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	[PMID: 19419804]
HEL	EC₅₀	6 μM Compound: Ganciclovir	Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	10.1007/s00044-009-9248-y
HEL	EC₅₀	6.12 μM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy Antiviral activity against Human cytomegalovirus AD169 expressed in HEL cells assessed as reduction in plaque formation incubated for 7 days by Giemsa stain based microscopy	[PMID: 26291038]
HEL	IC₅₀	6.2 μg/mL Compound: GCV	Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%. Tested for the inhibitory concentration required to reduce cytomegalovirus (CMV) strain Davis plaque formation by 50%.	[PMID: 7877148]
HEL	EC₅₀	6.5 μM Compound: ganciclovir	Antiviral activity against CMV AD169 in human HEL cells after 7 days Antiviral activity against CMV AD169 in human HEL cells after 7 days	[PMID: 17672445]
HEL	IC₅₀	7 μM Compound: ganciclovir	Inhibition against DNA of uninfected HEL cells by incorporation of [3H]TdR. Inhibition against DNA of uninfected HEL cells by incorporation of [3H]TdR.	[PMID: 7752205]
HEL	EC₅₀	7.8 μM Compound: Gancyclovir, DHPG	Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in AD-169 strain HEL cell lines Effective concentration required to inhibit cytomegalo virus-induced cytopathicity by 50% in AD-169 strain HEL cell lines	[PMID: 11495586]
HEL	EC₅₀	8.7 μM Compound: GCV	Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days Antiviral activity against HCMV Davis in HEL cells assessed as reduction of virus plaque formation after 7 days	[PMID: 17622128]
HEL	EC₅₀	9.1 μM Compound: Ganciclovir	Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay Antiviral activity against HCMV AD169 infected in HEL cells by viral CPE assay	[PMID: 22858222]
HEL 299	CC₅₀	> 10 μg/mL Compound: GCV	Cytotoxic concentration of compound was tested against HEL299(human embryonic lung fibroblast) cells using cytotoxic assay Cytotoxic concentration of compound was tested against HEL299(human embryonic lung fibroblast) cells using cytotoxic assay	[PMID: 11262090]
HEL 299	CC₅₀	> 100 μM Compound: 1b	Cytotoxicity against human HEL299 cells after 3 days by MTT assay Cytotoxicity against human HEL299 cells after 3 days by MTT assay	[PMID: 26460883]
HEL 299	CC₅₀	> 100 μM Compound: ganciclovir	In vitro cytotoxicity of the compound (Concentration required to reduce OD value by 50%) in human embryonic lung fibroblast(HEL 299) cells determined by MTT assay. In vitro cytotoxicity of the compound (Concentration required to reduce OD value by 50%) in human embryonic lung fibroblast(HEL 299) cells determined by MTT assay.	[PMID: 9925738]
HEL 299	CC₅₀	> 333 μM Compound: GCV, Ganciclovir	Cytotoxicity against HEL299 cells infected with human cytomegalovirus after 7 days by alamar blue assay Cytotoxicity against HEL299 cells infected with human cytomegalovirus after 7 days by alamar blue assay	[PMID: 20047911]
HEL 299	CC₅₀	> 400 μg/mL Compound: ganciclovir	Compound was tested for its cytotoxicity against human embryonic lung fibroblast cells (HEL 299) by MTT dye reduction assay Compound was tested for its cytotoxicity against human embryonic lung fibroblast cells (HEL 299) by MTT dye reduction assay	10.1016/S0960-894X(00)80078-5
HEL 299	CC₅₀	> 50 μM Compound: GCV	Cytotoxicity against human HEL 299 cells assessed as cell death incubated for 168 hrs by MTS-based tetrazolium reduction assay Cytotoxicity against human HEL 299 cells assessed as cell death incubated for 168 hrs by MTS-based tetrazolium reduction assay	[PMID: 34147908]
HEL 299	EC₅₀	0.63 μM Compound: ganciclovir	In vitro antiviral (HCMV-AD169) activity of the compound (Concentration required to reduce 50% of the plaques) determined by plaque reduction assay. In vitro antiviral (HCMV-AD169) activity of the compound (Concentration required to reduce 50% of the plaques) determined by plaque reduction assay.	[PMID: 9925738]
HEL 299	EC₅₀	2.39 μM Compound: GCV, Ganciclovir	Antiviral activity against human cytomegalovirus infected in HEL299 cells after 7 days by GFP-based fluorescent reduction assay Antiviral activity against human cytomegalovirus infected in HEL299 cells after 7 days by GFP-based fluorescent reduction assay	[PMID: 20047911]
HeLa	EC₅₀	> 100 μM Compound: Gancyclovir, DHPG	Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines	[PMID: 11495586]
HeLa	CC₅₀	221.8 μM Compound: Ganciclovir	Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay Cytotoxicity against human HeLa cells assessed as cell viability by colorimetric formazan-based MTS assay	[PMID: 22459876]
HEp-2	IC₅₀	> 100 μg/mL Compound: gancyclovir	Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days Cytotoxicity against mCMV RM-461 infected human Hep2 cells after 3 days	[PMID: 9599250]
HEp-2	EC₅₀	26.7 μg/mL Compound: gancyclovir	Antiviral activity against VZV 3CV-1 infected in human Hep2 cells after 3 days by plaque neutralization assay Antiviral activity against VZV 3CV-1 infected in human Hep2 cells after 3 days by plaque neutralization assay	[PMID: 9599250]
HEp-2	EC₅₀	5 μg/mL Compound: gancyclovir	Antiviral activity against mCMV RM461 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days Antiviral activity against mCMV RM461 infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days	[PMID: 9599250]
HEp-2	IC₅₀	840 μg/mL Compound: gancyclovir	Cytotoxicity against VZV 3CV-1 infected human Hep2 cells after 3 days Cytotoxicity against VZV 3CV-1 infected human Hep2 cells after 3 days	[PMID: 9599250]
HFF	CC₅₀	> 100 μM Compound: ganciclovir	Cytotoxicity against HFF cells by alamar blue assay Cytotoxicity against HFF cells by alamar blue assay	[PMID: 17329103]
HFF	CC₅₀	> 100 μM Compound: Ganciclovir	Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay	[PMID: 20403696]
HFF	CC₅₀	> 100 μM Compound: Ganciclovir	Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay Cytotoxicity against HFF cells after 3 days by neutral red dye uptake assay	[PMID: 18595689]
HFF	CC₅₀	> 100 μM Compound: GCV	Cytotoxicity against human HFF cells infected with Human cytomegalovirus AD169 assessed as viable cells by neutral red uptake assay Cytotoxicity against human HFF cells infected with Human cytomegalovirus AD169 assessed as viable cells by neutral red uptake assay	[PMID: 21376429]
HFF	CC₅₀	> 100 μM Compound: 10	Cytotoxicity against HFF cells by neutral red uptake assay Cytotoxicity against HFF cells by neutral red uptake assay	[PMID: 19397271]
HFF	CC₅₀	> 100 μM Compound: ganciclovir	Cytotoxicity against HFF cell by neutral red uptake assay Cytotoxicity against HFF cell by neutral red uptake assay	[PMID: 17004726]
HFF	CC₅₀	> 100 μM Compound: ganciclovir	Cytotoxicity against HFF cells after 3 days Cytotoxicity against HFF cells after 3 days	[PMID: 17434304]
HFF	IC₅₀	> 100 μM Compound: GCV	Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay Cytotoxicity against HFF cells after 48 hrs by visual cytotoxicity observation assay	[PMID: 21812420]
HFF	IC₅₀	> 100 μM Compound: Ganciclovir (DHPG)	Cytotoxicity in HFF cells was estimated by the visual scoring of cells affected by virus infection in the plaque reduction assay (data of single experiment) Cytotoxicity in HFF cells was estimated by the visual scoring of cells affected by virus infection in the plaque reduction assay (data of single experiment)	[PMID: 9057866]
HFF	IC₅₀	> 100 μM Compound: ganciclovir	Cytotoxicity produced in human foreskin fibroblasts (HFF) cells was estimated by visual scoring of cells unaffected by virus infection in the plaque-reduction assay. Cytotoxicity produced in human foreskin fibroblasts (HFF) cells was estimated by visual scoring of cells unaffected by virus infection in the plaque-reduction assay.	[PMID: 8784445]
HFF	IC₅₀	> 100 μM Compound: Ganciclovir (GCV)	Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection. Cytotoxicity produced in human foreskin fibroblasts (HFF) cells estimated by visual scoring of cells unaffected by virus infection.	[PMID: 8784444]
HFF	CC₅₀	> 100 μM Compound: 10	Cytotoxicity against HFF cells by plaque reduction assay Cytotoxicity against HFF cells by plaque reduction assay	[PMID: 19397271]
HFF	CC₅₀	> 100 μM Compound: ganciclovir	Cytotoxicity against HFF cells by visual cytotoxicity Cytotoxicity against HFF cells by visual cytotoxicity	[PMID: 15615545]
HFF	IC₅₀	> 100 μM Compound: GCV (table-1)	Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells	[PMID: 15509176]
HFF	IC₅₀	> 100 μM Compound: GCV (ganciclovir) (table-1)	Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells	[PMID: 15509175]
HFF	IC₅₀	> 100 μM Compound: GCV (ganciclovir) (table-1)	Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells Cytotoxicity produced in stationary HFF cells was determined by microscopic inspection of uninfected cells	[PMID: 15509174]
HFF	IC₅₀	> 100 μM Compound: GCV	Concentration required to inhibit stationary human HFF cell line growth was determined by microscopy examination Concentration required to inhibit stationary human HFF cell line growth was determined by microscopy examination	[PMID: 15509173]
HFF	IC₅₀	> 100 μM Compound: 1, Gancyclovir	Compound was tested for visual cytotoxicity on HFF cells unaffected by HCMV at the time of plaque enumeration Compound was tested for visual cytotoxicity on HFF cells unaffected by HCMV at the time of plaque enumeration	[PMID: 10882374]
HFF	CC₅₀	> 150 μM Compound: Ganciclovir	Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 14 days by cell titer glo assay Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 14 days by cell titer glo assay	[PMID: 34124679]
HFF	CC₅₀	> 150 μM Compound: Ganciclovir	Cytotoxicity against human HFF cells infected with HCMV AD-169 virus assessed as reduction in cell viability by cell titer-glo assay Cytotoxicity against human HFF cells infected with HCMV AD-169 virus assessed as reduction in cell viability by cell titer-glo assay	[PMID: 35754374]
HFF	CC₅₀	> 200 μM Compound: GCV	Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs or 10 days by MTT assay Cytotoxicity against human HFF cells assessed as reduction in cell viability incubated for 72 hrs or 10 days by MTT assay	[PMID: 32191456]
HFF	CC₅₀	> 300 μM Compound: GCV	Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining	[PMID: 22607883]
HFF	CC₅₀	> 392 μM Compound: ganciclovir	Cytotoxicity against HFF cells by neutral red uptake assay Cytotoxicity against HFF cells by neutral red uptake assay	[PMID: 15615545]
HFF	CC₅₀	> 392 μM Compound: Ganciclovir	Cytotoxic concentration against AD169 strain of human cytomegalovirus infected HFF cells of human (by neutral red uptake) Cytotoxic concentration against AD169 strain of human cytomegalovirus infected HFF cells of human (by neutral red uptake)	[PMID: 15634003]
HFF	CC₅₀	> 50 μM Compound: 1; GCV	Cytotoxicity against HFF cells assessed as cell viability incubated for 168 hrs by MTS-based Cell Titer assay Cytotoxicity against HFF cells assessed as cell viability incubated for 168 hrs by MTS-based Cell Titer assay	[PMID: 35377638]
HFF	EC₅₀	0.04 μM Compound: GCV	Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay Antiviral activity against Human cytomegalovirus (strain AD169) infected in 1 hr pretreated human HFF cells assessed as reduction in viral-induced cytopathic effect by neutral red uptake assay	[PMID: 21376429]
HFF	IC₅₀	0.14 μM Compound: GCV	Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay Antiviral activity against HCMV Towne infected in HFF cells incubated for 10 days by plaque reduction assay	[PMID: 21812420]
HFF	EC₅₀	0.15 μM Compound: ganciclovir	Inhibition of HCMV AD169 replication in HFF cells by cytopathic effect assay Inhibition of HCMV AD169 replication in HFF cells by cytopathic effect assay	[PMID: 17004726]
HFF	IC₅₀	0.6 μM Compound: Ganciclovir	Antiviral activity in a cell-based plaque reduction assay, using an HFF cell line and the Davis strain of HCMV Antiviral activity in a cell-based plaque reduction assay, using an HFF cell line and the Davis strain of HCMV	[PMID: 10999475]
HFF	IC₅₀	0.8 μM Compound: ganciclovir	Antiviral activity against human cytomegalovirus Ad169 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO Antiviral activity against human cytomegalovirus Ad169 (WT) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO	[PMID: 16134946]
HFF	IC₅₀	0.8 μM Compound: ganciclovir	Antiviral activity against human cytomegalovirus Ad169 (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO Antiviral activity against human cytomegalovirus Ad169 (V823A) plaque forming unit grown on Human foreskin fibroblast cells upon incubation for 1 hour at 37 degrees C with compound dissolved in DMSO	[PMID: 16134946]
HFF	IC₅₀	1 μM Compound: ganciclovir	Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay Antiviral activity against HCMV infected HFF cells after 5 days by dot blot assay	[PMID: 17329103]
HFF	EC₅₀	1.1 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2211 infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	IC₅₀	1.2 μM Compound: GCV (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) wild type expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	1.2 μM Compound: GCV (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) D10 strain (UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	1.2 μM Compound: GCV (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) r56 strain (UL56 mutant gene) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	1.3 μM Compound: GCV	Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay Antiviral activity against Human CMV T2211 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	1.3 μM Compound: ganciclovir	Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO Antiviral activity against human cytomegalovirus (Davis strain) grown on human foreskin fibroblast cells determined by reduction in plaque formation upon incubation at 37 degrees C with the compound dissolved in DMSO	[PMID: 16134946]
HFF	IC₅₀	1.4 μM Compound: GCV	Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay Antiviral activity against Human CMV T2241 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	1.4 μM Compound: GCV	Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay Antiviral activity against Human CMV T2233 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	EC₅₀	1.8 μM Compound: ganciclovir	Inhibition of HCMV towne replication in HFF cells by plaque reduction assay Inhibition of HCMV towne replication in HFF cells by plaque reduction assay	[PMID: 17004726]
HFF	IC₅₀	1.9 μM Compound: GCV	Antiviral activity against Human CMV AD169 in HFF cells by PRA Antiviral activity against Human CMV AD169 in HFF cells by PRA	[PMID: 17043128]
HFF	IC₅₀	10 μM Compound: GCV	Antiviral activity against Human CMV T2293 in HFF cells by PRA Antiviral activity against Human CMV T2293 in HFF cells by PRA	[PMID: 17043128]
HFF	IC₅₀	12.4 μM Compound: GCV	Antiviral activity against Human CMV T2311 in HFF cells by PRA Antiviral activity against Human CMV T2311 in HFF cells by PRA	[PMID: 17043128]
HFF	IC₅₀	1300 nM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay Antiviral activity against Human cytomegalovirus infected in HFF cells by plaque reduction assay	[PMID: 20167488]
HFF	IC₅₀	1300 nM Compound: ganciclovir	Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay Antiviral activity against HCMV Davis in HFF cells by plaque reduction assay	[PMID: 17434304]
HFF	IC₅₀	16.4 μM Compound: GCV	Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay Antiviral activity against ganciclovir-resistant HCMV3 isolate replication in HFF cells by plaque reduction assay	[PMID: 19010684]
HFF	IC₅₀	2.1 μM Compound: GCV	Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay	[PMID: 22607883]
HFF	EC₅₀	2.1 μM Compound: ganciclovir	Inhibition of HCMV Towne replication in HFF cells by plaque reduction assay Inhibition of HCMV Towne replication in HFF cells by plaque reduction assay	[PMID: 15615545]
HFF	EC₅₀	2.2 μM Compound: ganciclovir	Inhibition of HCMV AD169 replication in HFF cells by CPE inhibition assay Inhibition of HCMV AD169 replication in HFF cells by CPE inhibition assay	[PMID: 15615545]
HFF	EC₅₀	2.5 μM Compound: 14	Antiviral activity against Human cytomegalovirus Towne infected in HFF cells by plaque reduction assay Antiviral activity against Human cytomegalovirus Towne infected in HFF cells by plaque reduction assay	[PMID: 18082410]
HFF	IC₅₀	2.5 μM Compound: GCV (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) C4 strain (UL56 + UL89 mutant gene) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	2.6 μM Compound: Ganciclovir	Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by cytopathic effect inhibition assay Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by cytopathic effect inhibition assay	[PMID: 9438017]
HFF	EC₅₀	2.6 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2417 with pol A809V mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	2.7 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2542 with pol T813S mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	IC₅₀	3 μM Compound: Ganciclovir	Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days Antiviral activity against Human cytomegalovirus Towne infected in HFF cells assessed as reduction in plaque formation after 10 days	[PMID: 21641218]
HFF	IC₅₀	3 μM Compound: ganciclovir	Antiviral activity against HCMV Towne in HFF cells by plaque reduction assay Antiviral activity against HCMV Towne in HFF cells by plaque reduction assay	[PMID: 17161946]
HFF	IC₅₀	3.22 μM Compound: GCV	Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay Antiviral activity against ganciclovir-sensitive HCMV1 isolate replication in HFF cells by plaque reduction assay	[PMID: 19010684]
HFF	EC₅₀	3.5 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2420 with pol G841A mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	3.9 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2258 with UL97 C592G mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	IC₅₀	30.2 μM Compound: GCV	Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay Antiviral activity against Human CMV T2311 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	4.1 μM Compound: 1, Gancyclovir	Compound was tested for antiviral activity against C-4 Towne strain of HCMV in yield reduction assay using HFF cells Compound was tested for antiviral activity against C-4 Towne strain of HCMV in yield reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	4.1 μM Compound: GCV	Antiviral activity against Human CMV T2291 in HFF cells by PRA Antiviral activity against Human CMV T2291 in HFF cells by PRA	[PMID: 17043128]
HFF	IC₅₀	4.5 μM Compound: 1, Gancyclovir	Compound was tested for antiviral activity against wild-type Towne strain of HCMV in yield reduction assay using HFF cells Compound was tested for antiviral activity against wild-type Towne strain of HCMV in yield reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	5.6 μM Compound: GCV	Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay Antiviral activity against Human CMV T2293 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	CC₅₀	550 μM Compound: GCV	Cytotoxicity against human foreskin fibroblast after 5 days by MTT assay Cytotoxicity against human foreskin fibroblast after 5 days by MTT assay	[PMID: 19015358]
HFF	CC₅₀	550 μM Compound: GCV	Cytotoxicity against human HFF by MTT assay Cytotoxicity against human HFF by MTT assay	[PMID: 20194695]
HFF	EC₅₀	6.1 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2784 with pol A809V UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	EC₅₀	6.6 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV T2798 with pol T813S UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HFF	IC₅₀	7.1 μM Compound: GCV	Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay Antiviral activity against Human CMV T2291 in HFF cells by SEAP assay	[PMID: 17043128]
HFF	IC₅₀	7.4 μM Compound: 1, Gancyclovir	Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells Compound was tested for antiviral activity against Towne strain of HCMV in a plaque reduction assay using HFF cells	[PMID: 10882374]
HFF	IC₅₀	7.4 μM Compound: Ganciclovir	Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by plaque reduction assay Inhibitory concentration against human cytomegalovirus replication in HFF cells was determined by plaque reduction assay	[PMID: 9438017]
HFF	IC₅₀	7.4 μM Compound: GCV (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509176]
HFF	IC₅₀	7.4 μM Compound: GCV (ganciclovir) (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509175]
HFF	IC₅₀	7.4 μM Compound: GCV (ganciclovir) (table-1)	Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay Inhibitory concentration required against human cytomegalovirus (HCMV) expressed in HFF cells was determined by plaque reduction assay	[PMID: 15509174]
HFF	IC₅₀	7.4 μM Compound: Ganciclovir	Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells Compound was tested for antiviral activity against human cytomegalovirus (HCMV) by plaque reduction assay using HFF cells	[PMID: 10882375]
HFF	IC₅₀	7.4 μM Compound: Ganciclovir	Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells Antiviral activity against HCMV was determined by plaque reduction assay using HFF cells	[PMID: 10882372]
HFF	IC₅₀	7.4 μM Compound: Ganciclovir	Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells Antiviral activity against towne strain HCMV was determined by plaque reduction assay in duplicate wells using HFF cells	[PMID: 10882370]
HFF	IC₅₀	7.7 μM Compound: Ganciclovir (DHPG)	Antiviral activity was determined by the HCMV plaque assay using HFF cells Antiviral activity was determined by the HCMV plaque assay using HFF cells	[PMID: 9057866]
HFF	IC₅₀	8.4 μM Compound: Ganciclovir	In vitro inhibition of human cytomegalovirus in HFF cells by plaque reduction assay. In vitro inhibition of human cytomegalovirus in HFF cells by plaque reduction assay.	10.1016/S0960-894X(00)80470-9
HFF	EC₅₀	8.4 μM Compound: GCV	Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay Antiviral activity against Cytomegalovirus CMV 2817 with pol G841A UL97 C592G double mutant infected in HFF cells by SEAP reporter gene assay	[PMID: 17709468]
HS27	CC₅₀	> 333 μM Compound: GCV, Ganciclovir	Cytotoxicity against human HS27 cells infected with human cytomegalovirus after 7 days by alamar blue assay Cytotoxicity against human HS27 cells infected with human cytomegalovirus after 7 days by alamar blue assay	[PMID: 20047911]
HS27	EC₅₀	0.32 μM Compound: GCV, Ganciclovir	Antiviral activity against human cytomegalovirus infected in human HS27 cells after 7 days by GFP-based fluorescent reduction assay Antiviral activity against human cytomegalovirus infected in human HS27 cells after 7 days by GFP-based fluorescent reduction assay	[PMID: 20047911]
Hs68	CC₅₀	12.5 μg/mL Compound: GCV	Cytotoxic activity in Hs 68 cell line by inhibition of cell proliferation Cytotoxic activity in Hs 68 cell line by inhibition of cell proliferation	[PMID: 10888336]
Jurkat	CC₅₀	> 100 μM Compound: ganciclovir	Cytotoxicity against human Jurkat cells by alamar blue assay Cytotoxicity against human Jurkat cells by alamar blue assay	[PMID: 17329103]
KB	IC₅₀	> 100 μM Compound: Ganciclovir	Compound was evaluated for the cytotoxicity by the inhibition of KB cell growth. Compound was evaluated for the cytotoxicity by the inhibition of KB cell growth.	[PMID: 9575044]
KB	IC₅₀	> 100 μM Compound: Ganciclovir	Cytotoxicity for the compound was determined by the inhibition of the growing KB cells. Cytotoxicity for the compound was determined by the inhibition of the growing KB cells.	[PMID: 9548814]
KB	IC₅₀	> 100 μM Compound: GCV (table-1)	Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells	[PMID: 15509176]
KB	IC₅₀	> 100 μM Compound: GCV (ganciclovir) (table-1)	Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells	[PMID: 15509175]
KB	IC₅₀	> 100 μM Compound: GCV (ganciclovir) (table-1)	Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells Cytotoxicity against KB cells was determined by crystal violet staining and spectrophotometric quantitation of dye eluted from stained cells	[PMID: 15509174]
KB	IC₅₀	> 100 μM Compound: GCV	Concentration required to inhibit KB cell line growth was determined by crystal violet staining method Concentration required to inhibit KB cell line growth was determined by crystal violet staining method	[PMID: 15509173]
KB	IC₅₀	> 100 μM Compound: Ganciclovir	Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB). Cytotoxicity of compound was determined by assaying cell growth in human neoplastic cell line(KB).	[PMID: 1310744]
KB	IC₅₀	3.5 μM Compound: Ganciclovir (DHPG)	Antiviral activity was estimated by HSV-1 ELISA method (data of single experiment) Antiviral activity was estimated by HSV-1 ELISA method (data of single experiment)	[PMID: 9057866]
MEF	EC₅₀	0.96 μM Compound: GCV	Antiviral activity against Mouse Cytomegalovirus Smith (ATCC VR-1399) infected in mouse MEF cells assessed as reduction in plaque formation measured after 3 days by crystal violet staining based assay Antiviral activity against Mouse Cytomegalovirus Smith (ATCC VR-1399) infected in mouse MEF cells assessed as reduction in plaque formation measured after 3 days by crystal violet staining based assay	[PMID: 32191456]
MEF	IC₅₀	3.4 μM Compound: Ganciclovir	Inhibitory concentration against murine cytomegalovirus replication in MEF cells was determined by plaque reduction assay Inhibitory concentration against murine cytomegalovirus replication in MEF cells was determined by plaque reduction assay	[PMID: 9438017]
MRC5	CC₅₀	> 100 μg/mL Compound: Ganciclovir	Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation. Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.	[PMID: 9934471]
MRC5	CC₅₀	> 100 μM Compound: 1	Cytotoxicity against human MRC5 cells by CCK-8 assay Cytotoxicity against human MRC5 cells by CCK-8 assay	[PMID: 37037115]
MRC5	CC₅₀	> 333 μM Compound: GCV, Ganciclovir	Cytotoxicity against human MRC5 cells infected with human cytomegalovirus after 7 days by alamar blue assay Cytotoxicity against human MRC5 cells infected with human cytomegalovirus after 7 days by alamar blue assay	[PMID: 20047911]
MRC5	IC₅₀	0.91 μM Compound: GCV	Antiviral activity against HCMV in MRC5 cells by plaque reduction assay Antiviral activity against HCMV in MRC5 cells by plaque reduction assay	[PMID: 17239594]
MRC5	IC₅₀	1.2 μg/mL Compound: Ganciclovir	Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains P8 using MRC-5 cell line Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains P8 using MRC-5 cell line	[PMID: 15745823]
MRC5	EC₅₀	1.65 μM Compound: GCV, Ganciclovir	Antiviral activity against human cytomegalovirus infected in human MRC5 cells after 7 days by GFP-based fluorescent reduction assay Antiviral activity against human cytomegalovirus infected in human MRC5 cells after 7 days by GFP-based fluorescent reduction assay	[PMID: 20047911]
MRC5	IC₅₀	1.7 μM Compound: Ganciclovir	In vitro antiviral activity against Human cytomegalovirus (HCMV)strain AD169 in MRC-5 lung fibroblasts using a DNA-hybridization assay In vitro antiviral activity against Human cytomegalovirus (HCMV)strain AD169 in MRC-5 lung fibroblasts using a DNA-hybridization assay	[PMID: 8176714]
MRC5	IC₅₀	2.1 μg/mL Compound: Ganciclovir	Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation. Compound was tested for cytotoxicity by measuring inhibition of MRC-5 cell proliferation.	[PMID: 9934471]
MRC5	IC₅₀	2.2 μg/mL Compound: Ganciclovir	Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Ad169 using MRC-5 cell line Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory strains Ad169 using MRC-5 cell line	[PMID: 15745823]
MRC5	IC₅₀	30.1 μM Compound: GCV	Antiviral activity against Human CMV T2287 in MRC5 cells by PRA Antiviral activity against Human CMV T2287 in MRC5 cells by PRA	[PMID: 17043128]
MRC5	IC₅₀	4.9 μM Compound: GCV	Antiviral activity against Human CMV Towne in MRC5 cells by PRA Antiviral activity against Human CMV Towne in MRC5 cells by PRA	[PMID: 17043128]
MRC5	IC₅₀	5.4 μM Compound: GCV	Antiviral activity against Human CMV T2296 in MRC5 cells by PRA Antiviral activity against Human CMV T2296 in MRC5 cells by PRA	[PMID: 17043128]
MRC5	IC₅₀	5.9 μM Compound: ganciclovir	Concentration required to reduce viral plaque formation by Human Cytomegalovirus (HCMV) (strain AD-169) in MRC-5 cells Concentration required to reduce viral plaque formation by Human Cytomegalovirus (HCMV) (strain AD-169) in MRC-5 cells	[PMID: 10966740]
MRC5	IC₅₀	7.8 μg/mL Compound: Ganciclovir	Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains D16(UL54 mutation) using MRC-5 cell line Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains D16(UL54 mutation) using MRC-5 cell line	[PMID: 15745823]
MRC5	IC₅₀	8.7 μg/mL Compound: Ganciclovir	Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains C8704(UL97 mutation) using MRC-5 cell line Compound concentration to reduce virus plague formation by 50% tested against human cytomegalovirus laboratory mutant strains C8704(UL97 mutation) using MRC-5 cell line	[PMID: 15745823]
MRC5	CC₅₀	98 μM Compound: ganciclovir	Concentration required to reduce MRC-5 cell growth by 50% Concentration required to reduce MRC-5 cell growth by 50%	[PMID: 10966740]
MT4	IC₅₀	> 50 μM Compound: 1	Cytotoxicity against human MT4 cells assessed as reduction in cell viability by cell counting method Cytotoxicity against human MT4 cells assessed as reduction in cell viability by cell counting method	[PMID: 28829913]
NHDF	CC₅₀	> 333 μM Compound: GCV, Ganciclovir	Cytotoxicity against NHDF infected with human cytomegalovirus after 7 days by alamar blue assay Cytotoxicity against NHDF infected with human cytomegalovirus after 7 days by alamar blue assay	[PMID: 20047911]
NIH3T3	EC₅₀	5.7 μM Compound: GCV	Antiviral activity against Murine cytomegalovirus strain Smith infected in mouse NIH 3T3 cells after 4 to 5 days by plaque reduction assay Antiviral activity against Murine cytomegalovirus strain Smith infected in mouse NIH 3T3 cells after 4 to 5 days by plaque reduction assay	[PMID: 18458124]
RG2	CC₅₀	377 μM Compound: GCV	Cytotoxicity against RG2 cells after 72 hrs by MTT assay Cytotoxicity against RG2 cells after 72 hrs by MTT assay	[PMID: 18800764]
Vero	EC₅₀	> 50 μM Compound: ganciclovir	Inhibition of HSV1 in Vero cells by plaque reduction assay Inhibition of HSV1 in Vero cells by plaque reduction assay	[PMID: 15615545]
Vero	EC₅₀	> 50 μM Compound: ganciclovir	Inhibition of HSV2 in Vero cells by plaque reduction assay Inhibition of HSV2 in Vero cells by plaque reduction assay	[PMID: 15615545]
Vero	IC₅₀	0.1 μM Compound: 1 (BW-B759U, ganciclovir)	Inhibition of growth of herpes simplex virus (HSV-2) by plaque reduction assay in vero cell line Inhibition of growth of herpes simplex virus (HSV-2) by plaque reduction assay in vero cell line	[PMID: 2826784]
Vero	IC₅₀	0.1 μM Compound: 1 (BW-B759U, ganciclovir)	Inhibition of growth of herpes simplex virus (HSV-1) by plaque reduction assay in vero cell line Inhibition of growth of herpes simplex virus (HSV-1) by plaque reduction assay in vero cell line	[PMID: 2826784]
Vero	EC₅₀	0.23 μM Compound: Ganciclovir	Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50% Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell in monolayers of HSV-2 AD Vero cells by 50%	[PMID: 11585457]
Vero	EC₅₀	0.7 μM Compound: GCV	Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes simplex virus 1 F infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	0.9 μM Compound: 1b	Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay Antiviral activity against Herpes simplex virus 1 strain F VR-733 infected in African green monkey Vero cells after 3 days by MTT assay	[PMID: 26460883]
Vero	IC₅₀	1.22 μg/mL Compound: Ganciclovir	Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(G) using Vero cell line Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(G) using Vero cell line	[PMID: 15745823]
Vero	IC₅₀	1.274 μg/mL Compound: Ganciclovir	Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(KOS) using Vero cell line Compound concentration to reduce virus cytopathic effect by 50% tested against herpes simplex virus-1(KOS) using Vero cell line	[PMID: 15745823]
Vero	EC₅₀	1.4 μM Compound: 1b	Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay Antiviral activity against Herpes simplex virus 2 strain MS VR-540 infected in African green monkey Vero cells after 3 days by MTT assay	[PMID: 26460883]
Vero	EC₅₀	11.1 μM Compound: 1b	Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay Antiviral activity against Varicella-zoster virus Ellen VR-1367 infected in African green monkey Vero cells after 3 days by MTT assay	[PMID: 26460883]
Vero	EC₅₀	14.5 μM Compound: GCV	Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 24105 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	19.2 μM Compound: GCV	Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus E90-136 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate E2490 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR3 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR4 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR5 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR6 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR7 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR8 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR9 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR10 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR11 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MR2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A3 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A4 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A5 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate A6 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MC1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MC2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MJ1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MJ2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MJ3 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against Macacine herpesvirus 1 isolate MP1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against HSV1 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	19.3 μM Compound: GCV	Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay Antiviral activity against HSV2 infected in african green monkey Vero cells by plaque reduction assay	[PMID: 19858259]
Vero	EC₅₀	2.14 μM Compound: 1b	Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay Antiviral activity against Human cytomegalovirus Davis VR-807 infected in African green monkey Vero cells after 3 days by MTT assay	[PMID: 26460883]
Vero	IC₅₀	2.8 μM Compound: 1 (BW-B759U, ganciclovir)	Inhibition of growth of varicella zoster virus(VZV) by plaque reduction assay in vero cell line Inhibition of growth of varicella zoster virus(VZV) by plaque reduction assay in vero cell line	[PMID: 2826784]
Vero	EC₅₀	23.5 μM Compound: GCV	Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs Antiviral activity against Herpes B virus 32425 infected in african green monkey Vero cells assessed as plaque reduction after 36 to 48 hrs	[PMID: 17438061]
Vero	CC₅₀	666 μM Compound: GCV	Cytotoxicity against african green monkey Vero cells after 2 days Cytotoxicity against african green monkey Vero cells after 2 days	[PMID: 17438061]

In Vitro

Ganciclovir (BW 759) is an acyclic deoxyguanosine analog structurally similar to acyclovir but with superior activity against CMV. The median Ganciclovir concentration required to inhibit viral replication by 50 percent is 2.15 μM versus 72 μM for acyclovir^[4].
The primary mechanism of Ganciclovir action against CMV is inhibition of the replication of viral DNA by ganciclovir-5'-triphosphate (ganciclovir-TP). This inhibition includes a selective and potent inhibition of the viral DNA polymerase. Ganciclovir is metabolized to the triphosphate form by primarily three cellular enzymes: a deoxyguanosine kinase induced by CMV-infected cells; guanylate kinase; and phosphoglycerate kinase^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ganciclovir (BW 759) (50 mg/kg; i.p.; twice a day for five injections) significantly decreases white blood cells, red blood cells and platelets in newborn mice, and can diffuse into the brain and the perilymphatic space of the inner ear^[3].
Ganciclovir (1-80 mg/kg; i.h.; daily for 5 days) delays murine cytomegalovirus (MCMV)-induced wasting syndrome and mortality^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Non-inbred Oncins France 1 (OF1) mice and albino rats non-immunized for MCMV^[3]
Dosage:	50 mg/kg
Administration:	Intraperitoneal injection, twice a day for five injections (mice) or 3 days (adult rats) (Pharmacokinetic Study)
Result:	In adult rats, the intracochlear diffusion of Ganciclovir was shown to achieve the same concentration as in blood. In gestating mice, transplacental diffusion was observed, with a fetal-to-maternal blood ratio of 0.5. In newborn mice, the plasma concentration profile of Ganciclovir showed a peak at 2 h followed by a gradual decrease. In adult mice, the concentration peaked at 1 h, but became undetectable by 2 h after injection. Significantly decreased white blood cells, red blood cells and platelets in newborn mice.

Animal Model:	Female SCID mice inoculated with MCMV^[6]
Dosage:	0, 1, 10, 80 and 160 mg/kg
Administration:	Subcutaneous injection, once daily for 5 days
Result:	Dose dependently delayed the wasting syndrome and mortality in a dose range up to 80 mg/kg per day, whereas a dose of 160 mg/kg per day induced reversible side-effects.

Clinical Trial

Molecular Weight

255.23

Formula

C₉H₁₃N₅O₄

CAS No.

82410-32-0

Appearance

Solid

Color

White to off-white

SMILES

O=C1NC(N)=NC2=C1N=CN2COC(CO)CO

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 60 mg/mL (235.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 1.67 mg/mL (6.54 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.9180 mL	19.5899 mL	39.1797 mL
5 mM	0.7836 mL	3.9180 mL	7.8359 mL
10 mM	0.3918 mL	1.9590 mL	3.9180 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (8.15 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (8.15 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (8.15 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 3.33 mg/mL (13.05 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.89%

Select Batch:

Data Sheet (281 KB) SDS (418 KB)

COA (250 KB) HNMR (242 KB) RP-HPLC (262 KB)

Handling Instructions (2659 KB)

References

[1]. Faulds D, et al. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs. 1990;39(4):597-638. [Content Brief]

[2]. Maggs DJ, et al. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403. [Content Brief]

[3]. Boujemla I, et al. Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats. Antiviral Res. 2016;132:111-115. [Content Brief]

[4]. Fletcher CV, et al. Evaluation of ganciclovir for cytomegalovirus disease. DICP. 1989 Jan;23(1):5-12. [Content Brief]

[5]. Matthews T, et al. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis. 1988 Jul-Aug;10 Suppl 3:S490-4. [Content Brief]

[6]. Duan J, Paris W, Kibler P, Bousquet C, Liuzzi M, Cordingley MG. Dose and duration-dependence of ganciclovir treatment against murine cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res. 1998;39(3):189-197. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	3.9180 mL	19.5899 mL	39.1797 mL	97.9493 mL
H₂O / DMSO	5 mM	0.7836 mL	3.9180 mL	7.8359 mL	19.5899 mL
DMSO	10 mM	0.3918 mL	1.9590 mL	3.9180 mL	9.7949 mL
	15 mM	0.2612 mL	1.3060 mL	2.6120 mL	6.5300 mL
	20 mM	0.1959 mL	0.9795 mL	1.9590 mL	4.8975 mL
	25 mM	0.1567 mL	0.7836 mL	1.5672 mL	3.9180 mL
	30 mM	0.1306 mL	0.6530 mL	1.3060 mL	3.2650 mL
	40 mM	0.0979 mL	0.4897 mL	0.9795 mL	2.4487 mL
	50 mM	0.0784 mL	0.3918 mL	0.7836 mL	1.9590 mL
	60 mM	0.0653 mL	0.3265 mL	0.6530 mL	1.6325 mL
	80 mM	0.0490 mL	0.2449 mL	0.4897 mL	1.2244 mL
	100 mM	0.0392 mL	0.1959 mL	0.3918 mL	0.9795 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Ganciclovir Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Ganciclovir (Synonyms: BW 759; 2'-Nor-2'-deoxyguanosine)

Customer Review

Other Forms of Ganciclovir:

17 Publications Citing Use of MCE Ganciclovir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HSV Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Ganciclovir Related Classifications

Keywords:

Your Recently Viewed Products:

Ganciclovir (Synonyms: BW 759; 2'-Nor-2'-deoxyguanosine)

Customer Review

Other Forms of Ganciclovir:

Ganciclovir Related Antibodies

17 Publications Citing Use of MCE Ganciclovir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All HSV Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Ganciclovir Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Ganciclovir Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report